S47(3) NRTI's and INTSI's Flashcards
Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTIs) Class
Abacavir (Ziagen) Emtricitabine (Emtriva) Lamivudine (Epivir) Tenofovir disoproxil (Viread) Tenofovir alafenamide (Vemlidy)
Non- Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTIs) Class
Efavirenz (Sustiva)
Rilpivirine (Edurant)
Doravirine (Pifeltro)
Integrase Strand Transferase Inhibitor (INSTIs)
Raltegravir (Isentress)
Dolutegravir (Tivicay)
Bictegravir - ONLY IN COMBO as BICTARVY
Bictarvy is bictegravir/emtricitabime/tenofovir alofenamide
Protease Inhibitors
Darunavir (Prezista)
Ritonavir (Norvir)
Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTIs) Class are the backbone of therapy – ALWAYS HAVE TWO OF THESE!
MOA:
DNA analogue that prohibit reverse transcriptase of viral RNA to viral DNA thus stopping the life cycle and preventing further virions
Tenofovir (adenosine analogue), Abacavir (guanosine analogue)
Emtricitabine and lamivudine are both cytosine analogues
Use adenosine with cytosine
OR
Use guanosine with cytosine
If Abacavir is selected as drug to use what must be done prior?
Must get HLA 5701*B testing PRIOR to initiation
Significant hypersensitivity reaction
If allele is present, mark as drug allergy and NEVER challenge patient
Which patient should abacavir be avoided in?
Avoid if viral load > 100,000 copies
Avoid in patients with high cardiac risk
Be careful in patients with a sulfonamide allergy
Tenofovir disoproxil fumarate (TDF)
Renal impairment
Bone demineralization
Decrease in lipids
Available as a generic drug
Tenofovir alafenamide (TAF)
Weight gain especially when combined with an INSTI
Increase in lipids because it doesn’t decrease lipids like TDF
Only available in brand
Integrase Strand Transferase Inhibitor (INSTIs)
MOA:
Inhibits integrase enzyme within the nucleus in order to prevent viral DNA from inserting itself into host DNA
DDI w/ polyvalent cations
Bictarvy
Separate from cations by two hours before or six hours after
Risk for neural type defects for women of child bearing potential unknown
Weight gain
Dolutegravir
Separate from cations by two hours before or six hours after
Risk for neural type defects for women of child bearing potential
Weight gain
DDI with Rifampin
Cabotegravir
New drug awaiting approval
could be game changer as it is an IM formulation and shown to be superior to some other treatments